Bracco announces the birth of Bracco Japan Ltd Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Ltd.  as of April 1, 2023.

Patents

Quantification software VueBox® is a Bracco-patented, general-purpose software application for quantifying tissue perfusion using Dynamic Contrast-Enhanced Ultrasound (DCE-US).

Bracco è Marchio Storico di Interesse Nazionale L’azienda, nata nel 1927 e oggi leader globale nella diagnostica per immagini, entra a far parte dell’esclusivo gruppo di imprese storiche che rappresentano la punta di diamante del Made in Italy.

ACR Classifies Gadopiclenol as a Group II Agent Gadopiclenol solution for injection and Gadopiclenol Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 2023.

Our New Iodine Recollection Pilot and Re.Viva Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot 

BRACCO INVITES YOU @ RSNA 2023 Bracco Diagnostics Showcases Innovation and Collaborative Vision at RSNA 2023 Annual Meeting.

Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology The results of the multicenter, international PROMISE clinical trial demonstrate that gadopiclenol provides similar lesion visualization and contrast enhancement at a gadolinium dose of 0.05 mmol/kg versus a full dose of gadobutrol (0.1 mmol/kg).

Funding the Future of Radiology¹ With an over $1.8 million investment in radiology research, Bracco Diagnostics Inc. actively supports the advancement of the field by ensuring that 34 early-career radiological investigators have access to much-needed funding.

Innovating for the Future of Radiology¹ The impact of Bracco Diagnostics Inc.'s over $1.8 million investment has resulted in 59 manuscripts, six patents, two start-up businesses, and additional grant funding from the National Institutes of Health (NIH).